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Abstract
Human parvovirus B19V (B19V) has been associated with various haematological disorders, but data on its prevalence in leukaemia are
scarce. In this cross-sectional study, we investigated patients in Sao Paulo, Brazil with leukaemia to determine the molecular frequency of
B19 variants and characterize the viral genetic variability by partial and complete sequencing of the coding of non-structural protein 1 (NS1)/
viral capsid proteins 1 and 2 (VP1/VP2). The presence of B19V infections was investigated by PCR ampliﬁcation of the viral NS1 gene
fragment and conﬁrmed by sequencing analysis. The NS1/VP1/VP2 and partially larger gene fragments of the NS1-positive samples were
determined by overlapping nested PCR and direct sequencing results. The B19V NS1 was detected in 40 (16%) of 249 bone marrow samples
including 12/78 (15.4%) acute lymphoblastic leukaemia, 25/155 (16.1%) acute myeloid leukaemia and 3/16 (18.7%) chronic myeloid leukaemia
samples. Of the 40 participants, 25 (62.5%) were infected with genotype 1a and 15 (37.5%) with genotype 3b. The phylogenetic analysis of
other regions revealed that 12/40 (30%) of the patients with leukaemia were co-infected with genotypes 1a and 3b. In addition, a new B19V
intergenotypic recombinant (1a/3b) and an NS1 non-recombinant genotype 1a were detected in one patient. Our ﬁndings demonstrated a
relatively high prevalence of B19V monoinfections and dual infections and provide, for the ﬁrst time, evidence of inter-genotypic
recombination in adults with leukaemia that may contribute to the genetic diversity of B19V and may also be a source of new emerging viral
strains with future implications for diagnosis, therapy and efﬁcient vaccine development.
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Abstract
In France, about 40% of women aged 25–65 years do not participate in regular screening and thus are at high risk (HR) of cervical cancer.
Human papillomavirus (HPV) vaginal self-sampling is a valuable alternative in this population. This study aimed to assess the prevalence of HR
and LR (low-risk) HPV infection in 3767 women aged >35 years from mid-socioeconomic backgrounds who carried out HPV vaginal self-
sampling at home. HPV vaginal self-sampling was better accepted than the Pap-test in women aged 35–69 years who were previously non-
responders to individual invitation. From the 933 self-collected swabs studied (24.7%), 62 were HPV-infected (6.6%), and 73 HPV types
were found. HPV 16 was the most frequently found (43.5%), followed by 53 (23.2%), 18 (12.3%), 66 (12.3%), 31 (6.8%), 33 (5.4%) and 58
(2.7%). Ten women (16.2%) were infected by multiple HR-HPV types. Median HPV 16 load was 104.000 copies/106 cells and median HPV 18
load was 833 copies/106 cells. Six women (9.3%) harboured LR-HPV types. The 12-month follow-up of 43 HR-HPV positive women (69.3%)
revealed CIN2–3 lesions in three women (6.9%), all HPV 16 infected, and harbouring an HPV 16 load >5 log10 copies/10
6 cells. Women
harbouring HR-HPV types other than HPV 16/18 were older than women harbouring HPV 16/18 types (55 years vs. 46.9 years, p 0.0008).
The high frequency of HR-HPV types in women >50 years deserves further investigation to elucidate the mechanism involved (re-infection
or reactivation).
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